Her general practitioner diagnosed gouty arthritis because of a high serum uric-acid level (600 µmol/l; normal range 270–380 µmol/l) coexistent with tophi in her hands, and initiated ...

Shanton's Phase 2b study is a six-month, multi-center, randomized, double-blind, placebo-controlled, dose-ranging clinical study in refractory gout patients with or without tophi, to evaluate the ...

The group with pure gout was further stratified into patients with tophi (n = 21) and those without (n = 59). Seventy-two sex- and age-matched normal adults served as the control group.

Tophi are a symptom of gout. They are large, hardened masses of uric acid crystals within and around the joints. These masses can cause pain, joint deformity, and limited range of motion.

dose-ranging clinical study in refractory gout patients with or without tophi, to evaluate the efficacy and safety of a 10, 30, or 60 mg tablet dose of SAP-001. The study enrolled 87 patients from ...

Arthrosi Therapeutics doses first patient in replicate pivotal phase 3 REDUCE 1 trial of lead compound AR882: San Diego Wednesday, March 19, 2025, 11:00 Hrs [IST] Arthrosi Therape ...

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...

and dissolve tophi in gout and tophaceous gout patients, today announced the completion of enrollment for its pivotal global Phase 3 REDUCE 2 trial. "We would like to thank the gout community for ...

and dissolve tophi in gout and tophaceous gout patients, today announced that it has dosed the first patient in REDUCE 1, the Company's second pivotal Phase 3 clinical trial evaluating AR882.